NASDAQ:EVLO
Evelo Biosciences, Inc.
- Stock
Market Cap
1.90K
Beta: 1.26
Volume Today
2.55K
Avg: 3.76M
PE Ratio
−0.01
PFCF: −0.01
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | ||||||||
average payables | 1.02M - | 5.32M 419.82% | 9.49M 78.26% | 14.79M 55.84% | 10.72M 27.53% | 1.68M 84.30% | ||
average receivables | ||||||||
book value per share | 29.47 - | 156.78 432.08% | 6.26 96.01% | 37.59 500.25% | 15.44 58.91% | 3.28 78.79% | -0.06 101.75% | |
capex per share | -6.67 - | -9.29 39.36% | -0.25 97.31% | -1.89 658.04% | -0.67 64.65% | -0.57 14.20% | -0.01 98.76% | |
capex to depreciation | -2.53 - | -2.09 17.29% | -2.82 35.14% | -1.72 39.11% | -0.65 62.07% | -0.69 5.13% | -0.30 55.95% | |
capex to operating cash flow | 0.10 - | 0.07 26.24% | 0.12 54.29% | 0.04 63.54% | 0.02 57.08% | 0.02 13.14% | 0.01 60.88% | |
capex to revenue | ||||||||
cash per share | 82.84 - | 203.94 146.18% | 9.27 95.45% | 48.60 424.26% | 34.88 28.22% | 25.87 25.84% | 0.55 97.87% | |
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | ||||||||
debt to assets | 0.53 - | 0.23 57.44% | 0.08 66.18% | 0.22 180.56% | 0.46 113.10% | 0.64 39.21% | 0.79 23.87% | |
debt to equity | 1.80 - | 0.34 81.14% | 0.09 73.49% | 0.33 263.00% | 1.37 319.50% | 6.50 374.70% | -10.24 257.72% | |
dividend yield | ||||||||
earnings yield | -0.22 - | -0.47 110.37% | -0.01 97.98% | -0.66 6,860.47% | -0.20 70.21% | -0.38 93.85% | -0.04 89.27% | |
enterprise value | 54.41M - | 31.73M 41.68% | 5.56B 17,406.44% | 71.85M 98.71% | 448.48M 524.19% | 309.02M 31.10% | 2.81B 809.33% | |
enterprise value over ebitda | -4.34 - | -1.19 72.63% | -95.61 7,943.81% | -0.83 99.13% | -4.88 486.63% | -2.69 44.90% | -25.92 863.90% | |
ev to operating cash flow | -4.42 - | -1.36 69.13% | -117.50 8,514.55% | -1.00 99.15% | -6.14 514.94% | -3.19 47.95% | -27.76 768.82% | |
ev to sales | ||||||||
free cash flow per share | -72.33 - | -133.34 84.36% | -2.41 98.19% | -46.84 1,842.22% | -37.68 19.54% | -37.14 1.45% | -1.17 96.85% | |
free cash flow yield | -0.23 - | -0.42 84.36% | -0.01 97.78% | -0.58 6,123.73% | -0.16 72.98% | -0.31 96.28% | -0.04 88.14% | |
graham net net | 13.29 - | 127.23 857.50% | 8.22 93.54% | 29.41 257.76% | 4.41 85.01% | -4.07 192.28% | -0.25 93.94% | |
graham number | 217.10 - | 726.34 234.57% | 18.63 97.44% | 212.68 1,041.85% | 128.41 39.62% | 58.34 54.56% | 1.30 97.77% | |
income quality | 0.92 - | 0.83 10.19% | 0.83 0.09% | 0.84 1.43% | 0.78 7.38% | 0.79 1.49% | 0.88 11.65% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -37.17 - | -82.32 121.45% | 43.57 152.92% | -31.95 173.33% | -23.22 27.33% | |||
interest debt per share | 52.95 - | 53.14 0.35% | 0.63 98.81% | 12.91 1,936.65% | 20.06 55.35% | 22.64 12.87% | 0.64 97.17% | |
inventory turnover | ||||||||
invested capital | 1.80 - | 0.34 81.14% | 0.09 73.49% | 0.33 263.00% | 1.37 319.50% | 6.50 374.70% | -10.24 257.72% | |
market cap | 60.01M - | 60.01M 0% | 5.69B 9,382.76% | 130.05M 97.71% | 477.30M 267.02% | 321.17M 32.71% | 2.81B 773.94% | |
net current asset value | 2.68M - | 24.39M 811.51% | 125.00M 412.47% | 47.11M 62.31% | 8.70M 81.53% | -8.18M 193.97% | -17.86M 118.39% | |
net debt to ebitda | 0.45 - | 1.06 136.81% | 2.33 120.34% | 0.67 71.13% | 0.31 53.46% | 0.11 66.29% | -0.03 127.91% | |
net income per share | -71.09 - | -149.55 110.37% | -2.46 98.35% | -53.49 2,072.14% | -47.45 11.28% | -46.18 2.67% | -1.31 97.16% | |
operating cash flow per share | -65.66 - | -124.05 88.93% | -2.16 98.26% | -44.94 1,979.03% | -37.01 17.64% | -36.56 1.22% | -1.16 96.82% | |
payables turnover | ||||||||
receivables turnover | ||||||||
research and ddevelopement to revenue | ||||||||
return on tangible assets | -0.72 - | -0.64 10.78% | -0.34 47.41% | -0.94 179.69% | -1.03 9.68% | -1.39 34.55% | -1.78 27.82% | |
revenue per share | ||||||||
roe | -2.41 - | -0.95 60.46% | -0.39 58.77% | -1.42 261.87% | -3.07 115.91% | -14.10 358.80% | 22.94 262.75% | |
roic | -0.86 - | -0.70 18.14% | -0.37 47.76% | -1.08 194.48% | -1.12 3.58% | -1.55 38.06% | -2.04 31.43% | |
sales general and administrative to revenue | ||||||||
shareholders equity per share | 29.47 - | 156.78 432.08% | 6.26 96.01% | 37.59 500.25% | 15.44 58.91% | 3.28 78.79% | -0.06 101.75% | |
stock based compensation to revenue | ||||||||
tangible asset value | 5.53M - | 29.40M 432.08% | 136.95M 365.77% | 60.20M 56.04% | 30.48M 49.36% | 8.67M 71.57% | -4.99M 157.60% | |
tangible book value per share | 29.47 - | 156.78 432.08% | 6.26 96.01% | 37.59 500.25% | 15.44 58.91% | 3.28 78.79% | -0.06 101.75% | |
working capital | 13.47M - | 34.94M 159.34% | 138.68M 296.94% | 68.09M 50.90% | 49.02M 28.00% | 53.66M 9.46% | 39.18M 26.99% |
All numbers in USD (except ratios and percentages)